Neutralizing Monoclonal Antibody: New Member of Therapeutic Armamentarium Against COVID-19

Many targeted treatment methods have focused on SARS-CoV-2's spike protein, along with neutralizing monoclonal antibodies (mAbs), which are recombinant proteins, may be employed as a kind of passive immunotherapy to reduce pathogenicity. While vaccines are still the best way to prevent COVID-19 infection, mAbs are an effective treatment for those who have already been infected, as well as having the potential to prevent infection in those who have already been exposed to SARS-CoV-2, which can be especially beneficial to certain high-risk groups. Due to the limited initial availability of these new treatments, it is essential to consider their larger potential and create methods for their optimal deployment in clinical practice. The objectives of this review is to answer the most commonly asked clinical questions from HCPs and patients about the target population, dose, interactions with other medicines and vaccines, duration of immunity, and variants.